Low Carbon MDIs
Leading the transition to low carbon MDI’s
H&T Presspart, market leader in MDI components, is leading the industry transition to lower global warming potential (GWP) propellants. Complementary to our broad MDI component portfolio,our Inhalation Product Technology Centre supports developments with both HFA152a and HFO1234ze with a wide range of services including GMP standard batch filling for clinical trials.
MDI Component Selection
Our teams have many years of experience bringing to market highly complex inhalers. We understand the interaction between device components, formulations and can accelerate customer programs with supporting them in selection of the most appropriate MDI can and actuator geometry to fit their product needs.
Surface Treatment
As the industry transitions to low GWP propellants, challenges can occur with formulation stability within the MDI canister. H&T Presspart’s fully industrialised Plasma treatment technology is proven to reduce drug degradation and deposition even with the most challenging formulations. Our Plasma surface treatment enhances formulation stability and ensures the performance of the MDI.
GMP Batch Filling
H&T Presspart offers GMP-compliant filling of MDI batches to support development programs and clinical trials using HFA-152a and HFO-1234ze propellants. Our filling capabilities accommodate all standard commercial valves and are compatible with both solution and suspension formulations.
Analytical Services
H&T Presspart offers comprehensive analytical services and in-vitro testing for MDIs with both HFA-152a and HFO-1234ze low GWP propellants. The full range of testing capabilities includes Delivered Dose Uniformity (DDU), Aerodynamic Particle Size Distribution (APSD), and Spray Pattern and Plume Geometry (SPPG), supporting both new product developments and product transfers.
